Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
——
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
——

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's remainder of fiscal year 2024?
MoonLake Immunotherapeutics (MLTX) reported remainder of fiscal year 2024 of $875K in Q1 2026.
How has MoonLake Immunotherapeutics's remainder of fiscal year 2024 changed year-over-year?
MoonLake Immunotherapeutics's remainder of fiscal year 2024 decreased by 23.0% year-over-year, from $1.14M to $875K.